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Abstract
Purpose In the MONITOR-GCSF study of chemotherapy-
induced (febrile) neutropenia with biosimilar filgrastim,
56.6% of patients were prophylacted according to amended
EORTC guidelines, but 17.4% were prophylacted below and
26.0% above guideline recommendations.
Methods MONITOR-GCSF is a prospective, observational
study of 1447 evaluable patients from 140 cancers centers in
12 European countries treated with myelosuppressive chemo-
therapy for up to 6 cycles receiving biosimilar GCSF prophylax-
is. Patients were classified as under-, correctly-, or over-
prophylacted with GCSF relative to guideline recommendations
based on their chemotherapy risk, individual risk factors, and
type of GCSF prophylaxis (primary versus secondary).
Results Differences between under- (17.4%), correctly-
(56.6%), or over-prophylacted (26.0%) groups were found in
terms of patient risk factors (age, performance status, history of
FN, comorbid conditions) aswell as prophylaxis patterns (type of
prophylaxis, day of GCSF initiation, and GCSF duration). Rates
of chemotherapy-induced neutropenia (CIN) (all grades), FN,
and CIN-related hospitalizations were consistently lower in
over-prophylacted patients relative to under- and correctly-
prophylacted patients. No differences were observed between
under- and correctly-prophylacted patients except for CIN/FN-
related chemotherapy disturbances. No GCSF safety differences
were found between groups (except for headaches).
Conclusions The real-world evidence provided by the
MONITOR-GCSF study indicates that providing GCSF sup-
port may yield better CIN, FN, and CIN/FN-related hospital-
ization outcomes if patients are prophylacted at levels above
guideline recommendations. Patients who are under-
prophylacted are at higher risk for disturbances to their che-
motherapy regimens. Our findings support the guideline rec-
ommendation that CIN/FN risk be assessed at the beginning
of each chemotherapy cycle.
Keywords Chemotherapy-induced neutropenia . Febrile
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Introduction
Evidence-based guidelines for the prophylaxis of chemotherapy-
induced (CIN) and febrile neutropenia (FN) of the European
* Ivo Abraham
iabraham@matrix45.com
1 Universitaetsklinikum Hamburg Eppendorf, Hamburg, Germany
2 Division of Medical Oncology, Department of
Hematology-Oncology, Hospital Clínic de Barcelona, University of
Barcelona, Barcelona, Spain
3 Institut Multidisciplinaire d’Oncologie, Clinique de Genolier,
Genolier, Switzerland
4 Medizinische Abteilung I – Onkologie und Haematologie,
Wilhelminenspital, Wien, Austria
5 Dipartimento di Oncologia e Ematologia, Azienda Ospedaliero
Universitaria S. Giovanni Battista di Torino, Torino, Italy
6 Matrix45, 6159 W Sunset Rd, Tucson, AZ 85743, USA
7 Universitaet Basel, Basel, Switzerland
8 Hexal AG, Holzkirchen, Germany
9 Center for Health Outcomes and PharmacoEconomic Research,
University of Arizona, Tucson, AZ, USA
Support Care Cancer
DOI 10.1007/s00520-017-3572-4
Organization for Research and Treatment of Cancer (EORTC)
[1] and the National Comprehensive Cancer Network (NCCN)
[2] recommend that clinical decision-making be based on the
relative myelotoxicity of patients’ chemotherapy therapy regi-
mens and the presence of potential risk factors. Prophylaxis with
granulocyte colony-stimulating factors (GCSF) is indicated for
patients treated with chemotherapy with an FN risk ≥20% and
for patients receiving chemotherapy with an FN risk of 10–20%
if they also present with risk factors. No prophylaxis is recom-
mended for patients given chemotherapy with an FN risk <10%.
The MONITOR-GCSF study was a pan-European multi-
center longitudinal prospective study of practice patterns and
outcomes associated with CIN/FN prophylaxis with
biosimilar filgrastim (EP2006, Zarzio®/ Zarxio®, Hexal AG/
Sandoz International GmbH) that includes 1447 evaluable
patients from 140 cancers centers in 12 European countries
treated with myelosuppressive chemotherapy across a total of
6213 cycles [3, 4]. This study used the EORTC guidelines [1]
as a framework, specifically the algorithm of evaluating the
myelotoxicity of the chemotherapy regimen and the associat-
ed FN risk (<10%, 10–20%, ≥20%) as well as the presence of
conditions with high risk (age ≥65 years) and increased FN
risk (advanced disease, history of FN, no antibiotic prophy-
laxis), as well as other factors associated with FN (poor per-
formance and/or nutritional status, female gender, hemoglobin
<12 g/dL, renal, cardiovascular, or liver disease). This algo-
rithm was amended by expert consensus to recommend sec-
ondary prophylaxis in patients who experienced a CIN or FN
episode in a prior cycle and receiving low-risk (<10%) or
medium-risk (10–20%) chemotherapy (Fig. 1). The amended
algorithm also specified that secondary prophylaxis was not
indicated for patients receiving chemotherapy regimens with
≥20% myelotoxicity or with 10–20% myelotoxicity but in the
presence of patient risk factors (as primary prophylaxis should
have been administered) or for patients treated with regimens
with <10% or 10–20% myelotoxicity but no CIN/FN in a
prior cycle.
We used this amended algorithm to classify patients ac-
cording to prophylaxis intensity level. As reported earlier, of
1444 classifiable patients, 817 (56.6%) were correctly-
prophylacted, 251 (17.4%) were under-prophylacted, and
376 (26.0%) were over-prophylacted (Fig. 1) [5]. Modeling
analyses revealed that under-prophylaxis was an independent
predictor of patients experiencing an FN episode or a CIN/FN-
related hospitalization [6]. In contrast, over-prophylaxis was
associatedwith a lowered risk for a CIN grade 4 or FN episode
or a CIN/FN-related hospitalization.
To further explore the impact of prophylaxis intensity be-
low or above guideline-recommended levels, we performed
analyses stratified by prophylaxis intensity (under/correctly/
over-prophylacted) that compare patients’ in terms of demo-
graphics and clinical status at the start of chemotherapy,
Zarzio® prophylaxis patterns, and clinical and safety
outcomes. In keeping with our prior reports [5, 6], we distin-
guish between results using patients and results using cycles
as the unit of analysis. The patient-level evaluations focus on
outcomes Bever^ experienced anytime during the whole peri-
od of chemotherapy and inform about patient outcomes across
this line of chemotherapy. The cycle-level analyses target out-
comes recorded during a particular cycle and from 1 cycle to
the next, and inform about outcomes as patients progress
through the cycles of chemotherapy.
Methods
The background and methodology of MONITOR-GCSF [3,
4] as well as the study sample’s demographics and clinical
status at baseline, Zarzio® prophylaxis, and outcomes [5]
have been described elsewhere. We summarize below ele-
ments relevant to the present analyses.
Design
MONITOR-GCSF is a prospective, real-world, observational
study of cancer patients receiving myelosuppressive chemo-
therapy, whose treating physicians prescribed CIN/FN pro-
phylaxis with biosimilar filgrastim (EP2006, Zarzio®) per
their best clinical judgment. Eligible were adults (age ≥18)
with stages 3 or 4 breast, ovarian, bladder, or lung cancer;
metastatic prostate cancer; and stages 3 or 4 diffuse large B-
cell lymphoma or multiple myeloma. Patients were followed
up for a maximum of six chemotherapy cycles. Patients were
classified as to prophylaxis intensity according the schematic
in Fig. 1.
Outcomes
The following outcomes were recorded at both the patient-
and cycle-levels: occurrence of an episode of CIN of any
grade (CIN1/4), specified further as CIN grades 3 or 4
(CIN3/4), CIN grade 4 (CIN4), or an FN episode; CIN/FN-
related hospitalization or chemotherapy disturbance (dose re-
duction, delay in administration of chemotherapy, cancelation
of administration of chemotherapy); and a (worst-case) com-
posite index of any of these outcomes occurring.
Specialized statistical issues
The Patient risk score (PRS) is the weighted sum (range 0–11)
of each of the eight patient risk factors associated with CIN/
FN specified in the EORTC guidelines [1] and was developed
by consensus by four of the authors (C.B., P.G., M.A., H.L).
Weights of three were assigned to age ≥65 and history of prior
FN; 1.5 to advanced disease and poor performance and/or
nutritional status; and 0.5 to no antibiotic prophylaxis, female
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gender, hemoglobin <12 g/dL, and renal, cardiovascular or
liver disease. A PRS ≥3 was used to consider a patient as
being at elevated risk for CIN/FN (Fig. 1).
Cycle data were Bnested^ under patients and patients under
centers, violating the assumption of statistical independence.
Hence we applied generalized estimating equations (GEE) [7],
which adjust standard errors based on within-cluster correla-
tions, to estimate adjusted odds ratios (OR) and 95% confi-
dence intervals (95%CI). We calculated ORs for each out-
come for each prophylaxis intensity cohort separately to de-
termine the odds of each outcome for each cohort, as well as in
pairwise combinations, to contrast the relative odds of one
prophylaxis intensity level against another level.
Chemotherapy disturbances were estimated for the cycle after
(lag = 1) the CIN/FN event occurred.
Results
Patients
Of the 1444 patients who could be classified as to pro-
phylaxis intensi ty, 817 (56.6%) were correct ly-
prophylacted, 251 (17.4%) were under-prophylacted, and
376 (26.0%) were over-prophylacted (Fig. 1; Table 1).
The three cohorts were similar in terms of gender and
history of repeated infections (both p = n.s.). They
differed in terms of average age (p < 0.001), with under-
prophylacted patients older and over-prophylacted pa-
tients younger than correctly-prophylacted patients. The
cohorts also varied in performance status (p = 0.011), with
proportionately more over-prophylacted patients having
ECOG 0/1 scores and more under-prophylacted patients
having ECOG 1/2 scores re la t ive to correc t ly-
prophylacted patients. When comparing the cohorts on
the EORTC risk factors, no differences were observed in
the proportions of female patients and those without anti-
biotic prophylaxis (both p = n.s.). However, there were
proportionately more under-prophylacted patients age
≥65 (p < 0.001), with a history of FN (p = 0.029), Hb
<12 g/dL (p < 0.001), and renal, cardiovascular, or liver
disease (p < 0.001). Both under- and over-prophylacted
patients had proportionately more patients with advanced
disease (p = 0.009) but fewer with poor performance and/
or nutritional status (p = 0.005) compared to correctly-
prophylacted patients. Mean PRS was highest among
under-prophylacted and lowest among over-prophylacted
patients (p < 0.001).
The over-prophylacted cohort included significantly more
patients with solid and fewer with hematological malignancies
compared to the under- and correctly-prophylacted cohorts
(p = 0.009), who did not differ from each other (p = n.s.).
Both the under- and over-prophylacted cohorts had propor-
tionately more patients previously treated with chemotherapy
Fig. 1 Treatment decision
relative to EORTC guidelines
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(p = 0.004); however, there were no differences between co-
horts as to whether this was in the adjuvant or meta-static
setting, nor the number of prior lines of chemotherapy (all
p = n.s.). Cohorts had similar rates of prior radiation therapy
(p = n.s.). There was an association between prophylaxis in-
tensity and chemotoxicity. All over-prophylacted patients
were treated with regimens with <10% (36.4%) and 10–20%
FN risk (63.6%), whereas all under-prophylacted patients
Table 1 Patient demographics
and clinical status, cancer and
CIN/FN history, and management
Under Correct Over p
251 (17.4%) 817 (56.6%) 376 (26.0%)
Demographics and clinical status
Gender n.s.
Male 45.0% 37.2% 37.8%
Female 55.0% 62.8% 62.2%




57.7 ± 9.5, 58 <0.001
ECOG performance status
0 31.5% 40.7% 47.4%
1 57.8% 46.1% 46.5%
2 9.9% 10.9% 4.2% 0.011
3 0.9% 2.4% 1.7%
4 0.0% 0.0% 0.3%
History of repeated infections 4.3% 2.3% 2.0% n.s.
FN risk factors (EORTC)
High risk
Age ≥ 65 years 61.4% 46.1% 17.3% <0.001
Increased risk
Advanced diseasea 15.3% 11.2% 18.2% 0.009
History of FN 6.5% 0.8% 1.8% 0.029
No antibiotic prophylaxis 90.0% 85.4% 91.6% n.s.
Other factors
Poor performance and/or nutritional
status
11.8% 16.2% 8.5% 0.005
Female gender 55.0% 62.8% 62.2% n.s.
Hemoglobin <12 g/dL 60.0% 34.4% 39.4% <0.001
Renal, cardiovascular, or liver disease 31.6% 24.7% 13.5% <0.001
Patient risk score (M ± SD, Mdn) 3.8 ± 2.0, 4 2.9 ± 2.0, 3 2.0 ± 1.6, 1.5 <0.001
Cancer
Tumor type 0.009
Solid 72.5% 73.7% 88.0%
Hematological 27.5% 26.3% 12.0%
Prior treatments
Chemotherapy 37.1% 26.9% 39.1% 0.004
Of these adjuvant in metastatic setting 41.8% 48.2% 50.4% n.s.
Of these prior lines of chemo 48.1% 47.7% 56.1% n.s.
1 42.1% 48.9% 60.3%
2 31.6% 27.3% 24.7% n.s.
≥3 26.3% 23.9% 15.1%
Radiation therapy 19.5% 16.9% 23.1% n.s.
Chemotoxicity <0.001
<10% 0.0% 2.1% 36.4%
10–20% 46.6% 36.0% 63.6%
≥20% 53.4% 61.9% 0.0%
a Stage 4 (stage 3 if multiple myeloma) and prior chemotherapy in metastatic setting n.s. not significant
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received chemotherapy with 10–20% (46.6%) and ≥20%
(53.4%) FN risk. 61.9% of correctly-prophylacted patients
were administered regimens with ≥20% FN risk (p < 0.001).
Prophylaxis patterns
All under-prophylacted patients received secondary prophy-
laxis only, almost all (92.4%) of correctly-prophylacted pa-
tients had primary prophylaxis, whereas 76.6% of over-
prophylacted patients were given primary and 23.4% second-
ary prophylaxis (p < 0.001) (Table 2). The median day of
Zarzio® initiation was the second day after chemotherapy;
however, the mean initiation day for over-prophylacted pa-
tients was 2.70 days post-chemotherapy, compared to 2.99
for under- and 3.26 for correctly-prophylacted patients
(p = 0.001). Further, 19.5% of over-prophylacted patients
were initiated on the day of chemotherapy completion, com-
pared to 12.1 and 11.2% of, respectively, under- and correctly-
prophylacted patients. Despite a similar median prophylaxis
duration of 5 days across all three cohorts, mean duration was
shortest for over-prophylacted and longest for under-
prophylacted patients (p < 0.001). Cohorts did not differ in
terms of proportions of patients given 30 MIU/day versus
40 MIU/day of Zarzio®.
Outcomes
Consistently, whether in the patient- or the cycle-level analy-
ses, the three cohorts differed overall in the observed rates of
CIN1/4, CIN3/4, CIN4, and FN, CIN/FN-related hospitaliza-
tions, and the composite outcome score (all p ≤ 0.001)
(Table 3). The proportions of patients experiencing CIN/FN-
related chemotherapy disturbances were not statistically dif-
ferent across cohorts (p = n.s.); however, the proportion of
cycles with chemotherapy disturbances was highest among
under-prophylacted patients (p = 0.032).
Pairwise contrast analyses at the patient-level showed that,
generally, the likelihood of CIN and FN episodes anytime
during chemotherapy did not differ between under- and
correctly-prophylacted patients (all p = n.s.) (Table 4).
However, over-prophylacted patients were less likely to expe-
rience CIN/FN than correctly-prophylacted patients ever dur-
ing chemotherapy (all p < 0.001) or in any given cycle
(p < 0.001 for all CIN, p = 0.004 for FN). Compared to
over-prophylacted patients, under-prophylacted patients had
a greater likelihood of CIN and FN anytime during chemo-
therapy (p = 0.044 to p < 0.001).
Pairwise contrast analyses at the cycle-level revealed that
the likelihood of CIN/FN in a given cycle did not differ be-
tween under- and correctly-prophylacted patients (all p = n.s.)
(Table 4). Over-prophylacted patients were less likely to ex-
perience CIN/FN than correctly-prophylacted patients in any
given cycle (p < 0.001 for all CIN, p = 0.004 for FN). Under-
prophylacted patients had a greater likelihood of CIN and FN
in any given cycle compared to over-prophylacted patients
(p = 0.025 to p < 0.001).
Safety
With the exception of proportionately fewer under-
prophylacted patients experiencing headaches (p = 0.027), dif-
ferences between cohorts in the rates of patients reporting
clinical events of interest during the course of chemotherapy
were not statistically significant (all p = n.s.) (Table 5).
Reported rates of adverse drug reactions over 6142 cycles
were statistically similar across the three cohorts (p = n.s.).
Discussion
By the time of the approval of Zarzio® by the European
Medicines Agency in 2008 and the launch of the
MONITOR-GCSF study in 2010, two decades of evi-
dence with reference filgrastim had accumulated. Much
of this was summarized in, for example, the original [8]
and updated EORTC guidelines [1] and in systematic re-
views and meta-analyses [9- 16]. In the process, it became
apparent that the normative, trial-based prophylaxis pat-
tern of treating with standard GCSFs through the nadir of
the absolute neutrophil count (ANC) was being replaced
with shorter regimens varying across tumor types in the
average number of injections [17].
The relative maturity of the clinical experience with stan-
dard GCSFs in routine clinical practice was documented in
our earlier report on treatment patterns and outcomes in the
MONITOR-GCSF study [5]. The median duration of prophy-
laxis was 5 days, and there were no differences in mean dura-
tion between patients receiving primary and those receiving
secondary prophylaxis and when comparing oncological ver-
sus hematological patients. However, mean durations were
progressively longer as the relative FN risk of patients’ che-
motherapy regimens rose from <10% (M = 4.59 days) to 10–
20% (M = 4.98) and ≥20% (M = 5.33) (p < 0.001). Also noted
were differences in prophylaxis intensity relative to the
amended EORTC guidelines used in the MONITOR-GCSF
study. Slightly over half of patients (56.6%) were
prophylacted relative to the guidelines, about one in six pa-
tients received less prophylaxis than recommended, and about
a quarter were administered more prophylaxis than advised by
the guidelines. These deviations from evidence-based guide-
lines in daily clinical practice suggest either questionable clin-
ical practice or may provide new real-world data to integrate
into guidelines as the evidence migrates from initial RCT-
based findings to incorporating real-world data from a mature
clinical experience base in GCSF support and CIN/FN
prophylaxis.
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The analyses stratified by prophylaxis intensity reported
here revealed that, compared to correctly-prophylacted pa-
tients, under-prophylacted patients were at no greater risk for
experiencing CIN (all grades) and FN episodes, nor for CIN/
FN-related hospitalizations, over the course of their chemo-
therapy regimen; though they were at increased risk for dis-
turbances to this regimen. Relative to over-prophylacted
patients, under-prophylacted patients were at significantly
higher risk for adverse outcomes over the period of chemo-
therapy, including a twofold increased risk for disruptions to
their chemotherapy regimen and a threefold greater likelihood
of CIN/FN-related hospitalizations. The apparent incremental
protective effect of over-prophylaxis was also evident from
comparisons to correctly-prophylacted patients. The odds of
Table 2 Zarzio® prophylaxis
patterns Type of prophylaxis Under Correct Over p
Primary 0.0% 92.4% 76.6% <0.001
Secondary 100.0% 7.6% 23.4%
Dose Under Correct Over
30 MIU/day 51.4% 53.4% 55.1% n.s.
48 MIU/day 48.6% 46.6% 44.9%
Day of initiationa Under Correct Over
0 (during chemo) 12.1% 11.2% 19.5% <0.001
1–3 (according to guidelines) 59.3% 55.2% 56.8%
4 or more (late) 28.6% 33.5% 23.7%
Mean SD Median
By prophylaxis decision 0.001
Under 2.99 3.01 2
Correct 3.26 2.99 2
Over 2.70 2.92 2
Duration of prophylaxis at baseline (days)
Under Correct Over
1 3.3% 2.6% 5.3%
2 5.3% 3.4% 10.5%
3 17.9% 12.1% 15.5%
4 3.7% 7.7% 4.7%
5 41.5% 46.8% 42.8%
6 5.3% 7.4% 6.4%
7 11.0% 11.5% 9.1%
8 3.3% 1.9% 2.2%
9 0.8% 1.5% 0.6%
10 2.0% 2.2% 0.8%
11 1.2% 0.4% 0.3%
12 1.2% 0.4% 0.0%
13 0.0% 0.3% 0.3%
14 2.9% 1.6% 1.4%
≥15 0.8% 0.2% 0.3%
Mean SD Median
By prophylaxis decision <0.001
under 5.44 2.70 5
correct 5.20 2.20 5
over 4.72 2.33 5
Duration (all visits) Under Correct Over
1–3 days 23.7% 18.0% 29.1% 0.001
4–5 days 47.1% 55.0% 50.7%
6 + days 29.2% 27.0% 20.2%
a Zarzio® initiation expressed in days after chemotherapy
0 same day, 1 1 day after, 2 2 days after, etc. n.s. not significant
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CIN or FN episodes during the course of chemotherapy were
significantly lowered, as were the odds for hospitalization.
This protective effect did not extend to preventing disruptions
to the chemotherapy regimen. As a caution, note that these and
similar results about prophylaxis intensity and CIN/FN out-
comes were obtained from association-based analyses.
The relative robustness of these findings at the patient-level
were confirmed in the cycle-level analyses. The likelihood of
CIN and FN episodes and CIN/FN-related hospitalizations
during a given cycle was not statistically different in under-
prophylacted patients when compared to correctly-
prophylacted patients, but was statistically different relative
to over-prophylacted patients. The likelihood of chemothera-
py regimens being changed in a subsequent cycle was greater
for under-prophylacted patients compared to other patients,
but not for correctly-prophylacted patients. The relative ro-
bustness of both the patient- and cycle-level findings was
underscored in the analyses of the composite outcome, which
was an index of the Bworst case scenario^ of experiencing CIN
grade 4, FN, CIN/FN-related hospitalizations, and/or CIN/
FN-related chemotherapy disturbances ever during the course
of chemotherapy or from 1 cycle to the next.
The patient- and cycle-level analyses of prophylaxis inten-
sity draw attention to some well-established CIN/FN risk fac-
tors that are ignored in some cases leading to under-
prophylaxis or are emphasized in other cases leading to
prophylaxis patterns Babove^ the guideline recommendation.
These include age 65 years or older, ECOG performance
score, tumor type, prior chemotherapy, and prior history of
FN.
Note in this regard that the cycle-level analyses affirmed
that CIN/FN outcomes may be a function of the cycle of
chemotherapy, not just of the chemotherapy regimen in gen-
eral. The results from these analyses enable clinicians to eval-
uate the risk of a CIN/FN episode at the start of each cycle, not
just at the start of chemotherapy. This is consistent with the
guideline recommendations to re-evaluate the risk of CIN/FN
at the beginning of each cycle and to take the necessary pre-
cautions to prevent adverse CIN/FN outcomes.
The findings that, generally, under- and correctly-
prophylacted patients were at similar risk of adverse CIN/FN
outcomes (except for chemotherapy disturbances) may seem
counter-intuitive as one would expect that the former would
have worse outcomes than the latter. Certainly, under-
prophylaxis is not indicated in general, in fact, the finding
confirms the general need for prophylaxis. Clinicians’
decision-making may play a role here, as they may choose
to deviate from guideline recommendations, rely on clinical
experience, determine CIN/FN prophylaxis on a case-by-case
basis, and, as a result, under-prophylact some patients treated
with less myelotoxic regimens, better clinical and perfor-
mance status, and fewer if any risk factors. In fact,
Table 3 Clinical outcomes at the patient and cycle levels by prophylaxis decision
Under Correct Over p
% 95% CI % 95% CI % 95% CI
Unit of analysis, patient
Neutropenia episodes
CIN grades 1 through 4 41.0% (32.7%–49.9%) 39.9% (32.8%–47.4%) 19.7% (14.4%–26.3%) <0.001
CIN grades 3 or 4 24.3% (18.3%–31.6%) 27.4% (21.3%–34.5%) 12.5% (8.5%–18.1%) <0.001
CIN grade 4 12.0% (8.2%–17.2%) 16.8% (12.4%–22.3%) 6.4% (3.9%–10.3%) <0.001
FN 5.2% (2.6%–10.0%) 8.0% (6.1%–10.3%) 2.1% (1.1%–4.1%) <0.001
CIN/FN-related hospitalizations 8.0% (4.8%–12.9%) 7.1% (5.0%–10.0%) 2.7% (1.4%–4.9%) 0.001
CIN/FN-related chemotherapy disturbancesa 14.7% (10.4%–20.5%) 8.8% (6.4%–12.1%) 7.7% (4.9%–11.9%) n.s.
CIN/FN-related composite outcomeb 24.7% (18.5%–32.2%) 26.0% (21.2%–31.4%) 13.0% (9.4%–17.8%) <0.001
Unit of analysis, cycle
Neutropenia episodes
CIN grades 1 through 4 17.9% (14.7%–21.7%) 16.0% (14.3%–17.9%) 8.3% (6.4%–10.7%) <0.001
CIN grades 3 or 4 9.5% (7.2%–12.4%) 9.4% (8.2%–10.9%) 3.8% (2.8%–5.3%) <0.001
CIN grade 4 4.0% (2.8%–5.8%) 4.8% (4.0%–5.8%) 1.7% (1.1%–2.7%) <0.001
FN 1.6% (0.9%–2.9%) 1.7% (1.3%–2.2%) 0.5% (0.2%–1.1%) <0.001
CIN/FN-related hospitalizations 2.5% (1.6%–4.1%) 1.6% (1.2%–2.2%) 0.6% (0.3%–1.1%) <0.001
CIN/FN-related chemotherapy disturbancesa 4.2% (3.1%–5.7%) 2.4% (1.9%–3.0%) 2.3% (1.6%–3.4%) 0.032
CIN/FN-related composite outcomeb 8.6% (6.7%–11.0%) 7.5% (6.5%–8.6%) 3.9% (2.9%–5.3%) <0.001
a Type of chemotherapy disturbances are not mutually exclusive. Any patient may have experienced more than one type. Measured with 1 cycle lag
b Includes any occurrence of CIN grade 4, FN, CIN/FN-related hospitalization, and/or CIN/FIN-related chemotherapy disturbance. CI confidence
interval n.s. not significant
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proportionately more under-prophylacted patients were male,
over the age of 65, with ECOG scores of 1 or 2, and generally
in poorer health compared to correctly-prophylacted patients.
Despite these differences, the prophylaxis patterns of both
Table 5 Safety outcomes by
prophylaxis decision Under Correct Over p
Clinical Events (patient level, n = 1447)
Bone pain 23.6% 28.5% 25.0% n.s.
Thrombocytopenia 19.4% 17.4% 17.7% n.s.
Serum LDH increase 16.6% 20.2% 14.4% n.s.
Muscle pain 12.1% 16.8% 16.1% n.s.
Joint pain 11.6% 15.9% 15.6% n.s.
Serum GGT increase 12.8% 14.9% 15.4% n.s.
Serum ALP increase 11.9% 13.3% 15.3% n.s.
Other neurological symptoms 8.7% 7.5% 7.4% n.s.
Headache 3.4% 8.9% 7.3% 0.027
Blood uric acid increase 9.3% 7.7% 5.0% n.s.
Confusion/altered mental status 3.5% 2.6% 4.6% n.s.
Epistaxis 1.8% 2.2% 2.5% n.s.
Bleeding other than GI, skin hemorrhage 2.6% 2.0% 2.8% n.s.
Splenomegaly 1.3% 1.2% 0.3% n.s.
GI bleeding 0.4% 0.9% 0.3% n.s.
Skin hemorrhage 0.4% 0.8% 0.3% n.s.
Adverse drug reactions (cycle-level, n = 6142) 2.3% 1.8% 1.5% n.s.
ALP alkaline phosphatase, GGT gamma glutamyl transpeptidase, GI gastro intestinal, LDH lactate dehydrogenase n.s.
not significant







OR 95% CI p OR 95% CI p OR 95% CI p
Unit of analysis, patient
Neutropenia episodes
CIN grades 1 through 4 1.048 0.720–1.527 n.s. 0.369 0.261–0.522 <0.001 2.840 1.859–4.339 <0.001
CIN grades 3 or 4 0.850 0.571–1.266 n.s. 0.378 0.261–0.547 <0.001 2.247 1.378–3.665 0.001
CIN grade 4 0.674 0.420–1.081 n.s. 0.338 0.206–0.555 <0.001 1.991 1.111–3.569 0.021
FN 0.632 0.301–1.326 n.s. 0.252 0.121–0.524 <0.001 2.513 1.025–6.157 0.044
CIN/FN-related hospitalizations 1.133 0.640–2.007 n.s. 0.358 0.195–0.657 <0.001 3.169 1.555–6.457 0.002
CIN/FN-related chemotherapy disturbancesa 1.789 1.141–2.806 0.011 0.865 0.553–1.353 n.s. 2.069 1.150–3.723 0.015
CIN/FN-related composite outcomeb 0.936 0.627–1.398 n.s. 0.428 0.293–0.624 <0.001 2.189 1.375–3.486 0.001
Unit of analysis, cycle
Neutropenia episodes
CIN grades 1 through 4 1.147 0.875–1.503 n.s. 0.475 0.348–0.648 <0.001 2.415 1.674–3.484 <0.001
CIN grades 3 or 4 1.006 0.718–1.411 n.s. 0.381 0.262–0.555 <0.001 2.638 1.679–4.146 <0.001
CIN grade 4 0.834 0.541–1.285 n.s. 0.348 0.213–0.569 <0.001 2.395 1.323–4.333 0.004
FN 0.926 0.482–1.779 n.s. 0.301 0.132–0.686 0.004 3.081 1.150–8.254 0.025
CIN/FN-related hospitalizations 1.588 0.895–2.818 n.s. 0.354 0.174–0.718 0.004 4.489 2.008–10.033 <0.001
CIN/FN-related chemotherapy disturbancesa 1.824 1.216–2.734 0.004 0.991 0.634–1.550 n.s. 1.840 1.124–3.012 0.015
CIN/FN-related composite outcomeb 1.169 0.855–1.599 n.s. 0.504 0.357–0.713 <0.001 2.318 1.532–3.505 <0.001
a Type of chemotherapy disturbances are not mutually exclusive. Any patient may have experienced more than one type. Measured with 1 cycle lag
b Includes any occurrence of CIN grade 4, FN, CIN/FN related hospitalization, and/or CIN/FIN-related chemotherapy disturbancen.s. not significant
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cohorts were similar in terms of Zarzio® dose, day of prophy-
laxis initiation, duration of prophylaxis, except that all under-
prophylacted patients were on secondary, and virtually all
correctly-prophylacted patients were on primary prophylaxis.
Our f indings point at the relat ive benef i t of
prophylacting at a higher intensity than recommended in
the guidelines. This does not mean that over-prophylaxis
is indicated across-the-board, but may merit consideration
for selected patients. Proportionally, over-prophylacted
patients tended to be younger; with no or minimal impair-
ment in performance status; with only a few presenting
with comorbid renal, cardiovascular, or liver; with lower
Patient Risk Scores; with mainly solid tumors in more
advanced stages of disease; having received a prior line
of chemotherapy; and currently being treated with regi-
mens with <10% or 10–20% FN risk. For instance, one-
third of patients (n = 466, 32.2%) in the study had stages
III or IV breast cancer. Of the 408 breast cancer patients
who had an ECOG score of 0 or 1, 28.4% were over-
prophylacted, slightly higher than (and contributing to)
the full sample rate of 26.0%. However, the over-
prophylaxis rate was 37.3% in stage IV breast cancer pa-
tients with ECOG score of 0 or 1, and 36.3% in stage III
patients with an ECOG score of 0.
Over-prophylaxis may indicate a Bplaying-it-sure-and-
safe^ approach among clinicians, by focusing on subgroups
of patients with a more balanced profile of risk factors in
which a more intense prophylaxis approach is believed to lead
to better outcomes. In contrast to the perhaps more benign
(relatively speaking, that is) profile of over-prophylacted pa-
tients, under-prophylacted patients were generally the oppo-
site: proportionately older, more impaired in performance,
with more of them presenting with major comorbid disease,
with more of them being treated for a hematological malig-
nancy, with ≥2 prior lines of chemotherapy, and currently
receiving myelotoxic chemotherapy regimens with 10–20%
or ≥20% FN risk. Of concern, this may reflect a trend in
routine clinical practice to ignore the interaction of patient risk
factors with the myelotoxicity of their chemotherapy regi-
mens, leading to inadequate CIN/FN prophylaxis. Worse, it
might reflect a trend to under-prophylact patients with a poor
prognosis.
Whether there is an association between prophylaxis
intensity and the occurrence of CIN/FN-related chemo-
therapy disturbances remains unclear, at least partially.
Whether at the chemotherapy regimen level or the chemo-
therapy cycle level, under-prophylaxis was associated
with an elevated risk of either dose reductions and de-
layed or canceled chemotherapy sessions.
The safety analyses revealed no differences in the rates of
clinical events between the three prophylaxis intensity co-
horts. The exception was headache, which was reported with
greater frequency in correctly- and over-prophylacted
patients. This might be related to the fact that under-
prophylacted patients received secondary prophylaxis and
therefore had less drug exposure. Likewise, the rates of ad-
verse drug reactions observed across cycles were similar
across the three cohorts. The safety profile corresponds to
what is known about standard filgrastim in general and
biosimilar filgrastim in particular [18].
The analyses reported here warrant some caution in
addition to limitations identified in our prior reports on
the MONITOR-GCSF study [5, 6]. We classified patients
into three levels of prophylaxis intensity, and further gra-
dations might be possible. However, this may render com-
parative analyses more unwieldly if not overwhelming
and yield differentiations that may not be clinically mean-
ingful. Future analyses should also attempt to identify
alternate methods for classifying patients into prophylaxis
intensity categories that go beyond the amended EORTC
assessment algorithm and take into account on-treatment
data and markers. Our analyses were associative and the
MONITOR-GCSF study was not designed to compare the
effect of different levels of prophylaxis intensity to each
other and an untreated control group. Such a comparison
may not show a difference in outcome, and randomized
controlled trials are necessary to evaluate the impact of
differential prophylaxis on CIN/FN outcomes. We had the
benefit of a large sample size. While lending statistical
power to the study, it may also yield statistically signifi-
cant results that may not necessarily be clinically
meaningful.
The conclusion that clinicians’ prophylaxis decisions
may have been driven in part by patient-specific factors
implies that, methodologically, there may have been a
patient selection bias. However, by the same token and
perhaps more relevant from a real-world evidence point
of view, this may reflect routine clinical practice. This
underscores the external validity of our findings.
Conclusion
The real-world evidence provided by the MONITOR-
GCSF study indicates that providing GCSF support may
yield better CIN, FN, and CIN/FN-related hospitalization
outcomes if patients are prophylacted at levels above
guideline recommendations. In contrast, patients who re-
ceived inadequate GCSF prophylaxis are at markedly
higher risk for poor outcomes. Our analyses show that
guidelines may not be followed due to clinicians expecta-
tion of therapeutic benefit and clinical outcome, and pro-
vide real-world evidence to be integrated into future
guidelines for GCSF prophylaxis in patients with solid
tumors and hematological malignancies.
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